Enanta Pharmaceuticals (ENTA) shares rallied 6.7% in the last trading session to close at $16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.6% gain over the past four weeks.The company’s lead candidate, zelicapavir, an oral, N-protein inhibitor, is being evaluated in two ongoing mid-stage studies to treat pediatric and adult patients with respiratory syncytial virus (RSV) infection. The company also has ...